CCCC
C4 Therapeutics, Inc.
Biotechnology
Market Cap$247M
5Y Perf.-88.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CCCC vs AUPH
Revenue, margins, valuation, and 5-year total return — side by side.
AUPH
Aurinia Pharmaceuticals Inc.
Biotechnology
Market Cap$2.00B
5Y Perf.-3.4%
CCCC vs AUPH — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CCCC | AUPH |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $247M | $2.00B |
| Revenue (TTM) | $36M | $283M |
| Net Income (TTM) | $-105M | $287M |
| Gross Margin | 95.0% | 88.5% |
| Operating Margin | -320.5% | 37.1% |
| Forward P/E | — | 18.6x |
| Total Debt | $60M | $75M |
| Cash & Equiv. | $75M | $80M |
CCCC vs AUPH — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CCCC
AUPH
| Stock | Oct 20 | May 26 | Return |
|---|---|---|---|
| C4 Therapeutics, In… (CCCC) | 100 | 12.0 | -88.0% |
| Aurinia Pharmaceuti… (AUPH) | 100 | 96.6 | -3.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CCCC vs AUPH
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: AUPH leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. C4 Therapeutics, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
CCCC
C4 Therapeutics, Inc.
The Momentum Pick
CCCC is the clearest fit if your priority is momentum.
- +98.7% vs AUPH's +86.7%
Best for: momentum
AUPH
Aurinia Pharmaceuticals Inc.
The Income Pick
AUPH carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.86
- Rev growth 20.4%, EPS growth 51.7%, 3Y rev CAGR 28.3%
- 5.1% 10Y total return vs CCCC's -88.3%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AUPH | 20.4% revenue growth vs CCCC's 1.0% |
| Quality / Margins | AUPH | 101.5% margin vs CCCC's -292.1% |
| Stability / Safety | AUPH | Beta 0.86 vs CCCC's 2.35, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CCCC | +98.7% vs AUPH's +86.7% |
| Efficiency (ROA) | AUPH | 38.2% ROA vs CCCC's -33.9%, ROIC 16.6% vs -33.5% |
CCCC vs AUPH — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
CCCC vs AUPH — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLAUPHLAGGINGCCCC
CCCCC4 Therapeutics, Inc.
1leads
AUPHAurinia Pharmaceutica…
4leads
6 Total Categories
CATEGORYLEADERvs CCCCMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
AUPH4/6
Valuation MetricsMultiples, price ratios, and targets
CCCC3/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
AUPH6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
AUPH4/6
Risk & VolatilityBeta, volatility, and downside exposure
AUPH2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
AUPH leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
AUPH is the larger business by revenue, generating $283M annually — 7.9x CCCC's $36M. AUPH is the more profitable business, keeping 101.5% of every revenue dollar as net income compared to CCCC's -2.9%. On growth, CCCC holds the edge at +112.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CCCCC4 Therapeutics, … | AUPHAurinia Pharmaceu… |
|---|---|---|
| RevenueTrailing 12 months | $36M | $283M |
| EBITDAEarnings before interest/tax | -$113M | $105M |
| Net IncomeAfter-tax profit | -$105M | $287M |
| Free Cash FlowCash after capex | -$99M | $135M |
| Gross MarginGross profit ÷ Revenue | +95.0% | +88.5% |
| Operating MarginEBIT ÷ Revenue | -3.2% | +37.1% |
| Net MarginNet income ÷ Revenue | -2.9% | +101.5% |
| FCF MarginFCF ÷ Revenue | -2.8% | +47.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +112.8% | +28.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +63.3% | +152.0% |
AUPH leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
CCCC leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
| Metric | CCCCC4 Therapeutics, … | AUPHAurinia Pharmaceu… |
|---|---|---|
| Market CapShares × price | $247M | $2.0B |
| Enterprise ValueMkt cap + debt − cash | $232M | $2.0B |
| Trailing P/EPrice ÷ TTM EPS | -2.35x | 7.31x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 18.62x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 19.04x |
| Price / SalesMarket cap ÷ Revenue | 6.87x | 7.08x |
| Price / BookPrice ÷ Book value/share | 0.96x | 3.61x |
| Price / FCFMarket cap ÷ FCF | — | 14.80x |
CCCC leads this category, winning 3 of 3 comparable metrics.
Profitability & Efficiency
AUPH leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
AUPH delivers a 49.4% return on equity — every $100 of shareholder capital generates $49 in annual profit, vs $-54 for CCCC. AUPH carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to CCCC's 0.23x. On the Piotroski fundamental quality scale (0–9), AUPH scores 7/9 vs CCCC's 3/9, reflecting strong financial health.
| Metric | CCCCC4 Therapeutics, … | AUPHAurinia Pharmaceu… |
|---|---|---|
| ROE (TTM)Return on equity | -53.8% | +49.4% |
| ROA (TTM)Return on assets | -33.9% | +38.2% |
| ROICReturn on invested capital | -33.5% | +16.6% |
| ROCEReturn on capital employed | -33.1% | +18.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 7 |
| Debt / EquityFinancial leverage | 0.23x | 0.13x |
| Net DebtTotal debt minus cash | -$15M | -$5M |
| Cash & Equiv.Liquid assets | $75M | $80M |
| Total DebtShort + long-term debt | $60M | $75M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
AUPH leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
AUPH leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AUPH five years ago would be worth $14,924 today (with dividends reinvested), compared to $869 for CCCC. Over the past 12 months, CCCC leads with a +98.7% total return vs AUPH's +86.7%. The 3-year compound annual growth rate (CAGR) favors AUPH at 10.6% vs CCCC's -2.6% — a key indicator of consistent wealth creation.
| Metric | CCCCC4 Therapeutics, … | AUPHAurinia Pharmaceu… |
|---|---|---|
| YTD ReturnYear-to-date | +54.4% | -1.4% |
| 1-Year ReturnPast 12 months | +98.7% | +86.7% |
| 3-Year ReturnCumulative with dividends | -7.7% | +35.3% |
| 5-Year ReturnCumulative with dividends | -91.3% | +49.2% |
| 10-Year ReturnCumulative with dividends | -88.3% | +508.0% |
| CAGR (3Y)Annualised 3-year return | -2.6% | +10.6% |
AUPH leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
AUPH leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
AUPH is the less volatile stock with a 0.86 beta — it tends to amplify market swings less than CCCC's 2.35 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AUPH currently trades 89.7% from its 52-week high vs CCCC's 78.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CCCCC4 Therapeutics, … | AUPHAurinia Pharmaceu… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.35x | 0.86x |
| 52-Week HighHighest price in past year | $3.82 | $16.88 |
| 52-Week LowLowest price in past year | $1.21 | $7.29 |
| % of 52W HighCurrent price vs 52-week peak | +78.0% | +89.7% |
| RSI (14)Momentum oscillator 0–100 | 53.4 | 58.3 |
| Avg Volume (50D)Average daily shares traded | 2.9M | 1.1M |
AUPH leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates CCCC as "Buy" and AUPH as "Buy". Consensus price targets imply 134.9% upside for CCCC (target: $7) vs 2.4% for AUPH (target: $16).
| Metric | CCCCC4 Therapeutics, … | AUPHAurinia Pharmaceu… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $7.00 | $15.50 |
| # AnalystsCovering analysts | 14 | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.1% | +4.9% |
Insufficient data to determine a leader in this category.
Key Takeaway
AUPH leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CCCC leads in 1 (Valuation Metrics).
Best OverallAurinia Pharmaceuticals Inc. (AUPH)Leads 4 of 6 categories
Loading custom metrics...
CCCC vs AUPH: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is CCCC or AUPH a better buy right now?
For growth investors, Aurinia Pharmaceuticals Inc.
(AUPH) is the stronger pick with 20. 4% revenue growth year-over-year, versus 1. 0% for C4 Therapeutics, Inc. (CCCC). Aurinia Pharmaceuticals Inc. (AUPH) offers the better valuation at 7. 3x trailing P/E (18. 6x forward), making it the more compelling value choice. Analysts rate C4 Therapeutics, Inc. (CCCC) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CCCC or AUPH?
Over the past 5 years, Aurinia Pharmaceuticals Inc.
(AUPH) delivered a total return of +49. 2%, compared to -91. 3% for C4 Therapeutics, Inc. (CCCC). Over 10 years, the gap is even starker: AUPH returned +508. 0% versus CCCC's -88. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CCCC or AUPH?
By beta (market sensitivity over 5 years), Aurinia Pharmaceuticals Inc.
(AUPH) is the lower-risk stock at 0. 86β versus C4 Therapeutics, Inc. 's 2. 35β — meaning CCCC is approximately 173% more volatile than AUPH relative to the S&P 500. On balance sheet safety, Aurinia Pharmaceuticals Inc. (AUPH) carries a lower debt/equity ratio of 13% versus 23% for C4 Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — CCCC or AUPH?
By revenue growth (latest reported year), Aurinia Pharmaceuticals Inc.
(AUPH) is pulling ahead at 20. 4% versus 1. 0% for C4 Therapeutics, Inc. (CCCC). On earnings-per-share growth, the picture is similar: Aurinia Pharmaceuticals Inc. grew EPS 51. 7% year-over-year, compared to 16. 4% for C4 Therapeutics, Inc.. Over a 3-year CAGR, AUPH leads at 28. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CCCC or AUPH?
Aurinia Pharmaceuticals Inc.
(AUPH) is the more profitable company, earning 101. 5% net margin versus -292. 1% for C4 Therapeutics, Inc. — meaning it keeps 101. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AUPH leads at 37. 1% versus -290. 7% for CCCC. At the gross margin level — before operating expenses — AUPH leads at 88. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CCCC or AUPH more undervalued right now?
Analyst consensus price targets imply the most upside for CCCC: 134.
9% to $7. 00.
07Which pays a better dividend — CCCC or AUPH?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is CCCC or AUPH better for a retirement portfolio?
For long-horizon retirement investors, Aurinia Pharmaceuticals Inc.
(AUPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 86), +508. 0% 10Y return). C4 Therapeutics, Inc. (CCCC) carries a higher beta of 2. 35 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AUPH: +508. 0%, CCCC: -88. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CCCC and AUPH?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CCCC is a small-cap quality compounder stock; AUPH is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(CCCC: 112.8% · AUPH: 28.8%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.